Most Read Articles
2 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Teprotumumab improves outcomes in thyroid eye disease

11 Mar 2020

Treatment with teprotumumab in patients with active thyroid eye disease confers beneficial effects on proptosis, Clinical Activity Score, diplopia and quality of life, without increasing the incidence of serious adverse events, according to the results of a phase III trial.

A total of 83 patients were randomized to receive teprotumumab (n=41) or placebo (n=42). Treatment was administered as intravenous infusions, with the active drug dosed at 10 mg/kg of body weight for the first infusion and 20 mg/kg for subsequent infusions, once every 3 weeks for 21 weeks. The last trial visit for the present analysis was at week 24.

The primary outcome of a proptosis response (reduction of ≥2 mm) at week 24 occurred with greater frequency in the teprotumumab vs placebo arm (83 percent vs 10 percent; p<0.001), with a number needed to treat of 1.36.

Results for all secondary outcomes were likewise more favourable with the active drug than with placebo: overall response (78 percent vs 7 percent), Clinical Activity Score of 0 or 1 (no or minimal inflammation; 59 percent vs 21 percent), the mean change in proptosis (−2.82 vs −0.54 mm), diplopia response (reduction of ≥1 grade; 68 percent vs 29 percent), and the mean change in Graves’ ophthalmopathy-specific quality-of-life overall score (13.79 vs 4.43 points; pall≤0.001).

Among patients who underwent orbital imaging, six showed improvements in extraocular muscle, orbital fat volume, or both.

Most adverse events were mild or moderate in severity; two serious events occurred in the teprotumumab group, of which one (an infusion reaction) led to treatment discontinuation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.